Alrestatin sodium

N/A

Report date: 2022/05/16 10:20:03
NME

Base Information

Drug NameAlrestatin sodium
Drug Alias Name阿司他丁AY-22844AY-22284A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAldose reductase inhibitors
TargetsAldose reductase
Therapy Area/IndicationsDiabetes Complications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Complications

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG